0001610717-23-000204.txt : 20230712 0001610717-23-000204.hdr.sgml : 20230712 20230712172529 ACCESSION NUMBER: 0001610717-23-000204 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230710 FILED AS OF DATE: 20230712 DATE AS OF CHANGE: 20230712 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Throne Jason CENTRAL INDEX KEY: 0001790865 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38915 FILM NUMBER: 231085352 MAIL ADDRESS: STREET 1: C/O IDEAYA BIOSCIENCES, INC. STREET 2: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 4 1 form4.xml X0407 4 2023-07-10 0001676725 IDEAYA Biosciences, Inc. IDYA 0001790865 Throne Jason C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 true Chief Legal Officer true Common Stock 2023-07-10 4 M 0 4485 7.01 A 4485 D Common Stock 2023-07-10 4 M 0 5000 12.86 A 9485 D Common Stock 2023-07-10 4 S 0 9485 23.0024 D 0 D Stock Option (Right to Buy) 7.01 2023-07-10 4 M 0 4485 0 D 2029-10-08 Common Stock 4485 58420 D Stock Option (Right to Buy) 12.86 2023-07-10 4 M 0 5000 0 D 2032-02-29 Common Stock 5000 58750 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023. This transaction was executed in multiple trades in prices ranging from $22.72 to $23.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 25% of the shares subject to the option vest on the first anniversary measured from October 9, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Jason Throne 2023-07-12